Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

D DX41 -Low Expression Mimics Germline DDX41 -Phenotype in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 820.

https://doi.org/10.1182/blood-2023-187419

Published: 2023

Journal Articles

Risk Stratification of Patients with RUNX1- mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2934.

https://doi.org/10.1182/blood-2023-174059

Published: 2023

Journal Articles

Genetic Characterization of Patients with Monoallelic and Biallelic CEBPA Mutations Using a Targeted Sequencing Approach Reveals Differences in the Spectrum of Cooperating Mutations

Nikola P Konstandin, Klaus H. Metzeler, MD, Annika Dufour, PhD, Philipp A Greif, MD, Tobias Herold, MD, Bianka Ksienzyk, Stephanie Schneider, Dr. rer. nat., Wolfgang E Berdel, MD, Thomas Büchner, MD, Bernhard J. Woermann, MD, Cristina Sauerland, MSc, Jan Braess, MD, Wolfgang Hiddemann, MD, Stefan K Bohlander, MD, Karsten Spiekermann, MD

Blood (2014) 124 (21): 2385.

https://doi.org/10.1182/blood.V124.21.2385.2385

Published: 2014

Journal Articles

Up-Front Randomization 10 Years Later: The AML Cooperative Group Strategy

Thomas Buchner, MD, Wolfgang E. Berdel, MD, Bernhard J. Woermann, MD, Maria Cristina Sauerland, MSc, Achim Heinecke, PhD, Utz Krug, MD, Wolfgang Hiddemann, MD

Blood (2014) 124 (21): 2267.

https://doi.org/10.1182/blood.V124.21.2267.2267

Published: 2014

Journal Articles

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

Blood (2014) 124 (8): 1304–1311.

https://doi.org/10.1182/blood-2013-12-540716

Published: 2014

Includes: Supplemental data

Journal Articles

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Blood (2013) 122 (21): 1303.

https://doi.org/10.1182/blood.V122.21.1303.1303

Published: 2013

Journal Articles

Activating FLT3 Mutations Display a Wide Range Of Transforming Potential and a Characteristic Pathway Profile Associated With Prognosis In Acute Myeloid Leukemia

Hanna Janke, Friederike Schneider, MD, Daniela Schumacher, Tobias Herold, MD, Hopfner Karl-Peter, PhD, Stephanie Schneider, PhD, Wolfgang E. Berdel, MD, Thomas Büchner, MD, Bernhard J. Woermann, MD, Marion Subklewe, MD, Stefan K. Bohlander, MD, Wolfgang Hiddemann, MD, Harald Polzer, PhD, Karsten Spiekermann, MD

Blood (2013) 122 (21): 1312.

https://doi.org/10.1182/blood.V122.21.1312.1312

Published: 2013

Journal Articles

Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis

Blood (2013) 122 (21): 608.

https://doi.org/10.1182/blood.V122.21.608.608

Published: 2013

Journal Articles

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Jan Braess, MD, Karl-Anton Kreuzer, Karsten Spiekermann, PhD, Hans Walter Lindemann, MD, Eva Lengfelder, MD, Ullrich Graeven, Peter Staib, MD, Wolf-Dieter Ludwig, Harald Biersack, Yon-Dschun Ko, MD, Michael J. Uppenkamp, Stefan Korsten, Maike De Wit, Rudolf Peceny, MD, Tobias Gaska, MD, Xaver Schiel, Dirk M Behringer, MD, Michael G. Kiehl, MD, PhD, Bettina Zinngrebe, Gerald Meckenstock, Eva Roemer, Dirk Medgenberg, Ernst Spaeth-Schwalbe, MD, Birgit Braess, MD, Gero Massenkeil, MD, Heidrun Hindahl, Guido Trenn, Rainer Schwerdtfeger, MD, Susanne Amler, MSc, Cristina Sauerland, MSc, Andreas Faldum, MD, Michael Unterhalt, M.D. Ph.D., Stefan K. Bohlander, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Christian Buske, MD, Michael Fiegl, MD, Marion Subklewe, MD, Anja Baumgartner, PhD, Bernhard J. Woermann, MD, Dietrich Beelen, MD, Wolfgang Hiddemann, MD

Blood (2013) 122 (21): 619.

https://doi.org/10.1182/blood.V122.21.619.619

Published: 2013

Journal Articles

Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity

Blood (2013) 122 (21): 1447.

https://doi.org/10.1182/blood.V122.21.1447.1447

Published: 2013

Journal Articles

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Blood (2013) 122 (10): 1761–1769.

https://doi.org/10.1182/blood-2013-01-476473

Published: 2013

Includes: Supplemental data

Journal Articles

Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis

Blood (2012) 120 (21): 1974.

https://doi.org/10.1182/blood.V120.21.1974.1974

Published: 2012

Journal Articles

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia

Blood (2012) 120 (2): 395–403.

https://doi.org/10.1182/blood-2012-01-403220

Published: 2012

Includes: Supplemental data

Journal Articles

Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group

Blood (2011) 118 (21): 425.

https://doi.org/10.1182/blood.V118.21.425.425

Published: 2011

Journal Articles

Follow-up Analysis of a Randomized Comparison of Prolonged Myelosuppressive Maintenance Therapy Versus Intensive Consolidation Therapy as Postremission Therapy in AML.

Utz O. Krug, MD, Maria Cristina Sauerland, PhD, Bernhard J Woermann, MD, Wolfgang Berdel, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD

Blood (2009) 114 (22): 1056.

https://doi.org/10.1182/blood.V114.22.1056.1056

Published: 2009

Journal Articles

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

Blood (2009) 114 (22): 485.

https://doi.org/10.1182/blood.V114.22.485.485

Published: 2009

Journal Articles

A Novel Risk Score Predicts the Likelihood of a Complete Remission After Intensive Induction Therapy in Older AML Patients.

Utz O. Krug, MD, Achim Heinecke, PhD, Anja Koschmieder, MD, Matthias Stelljes, MD, Maria Cristina Sauerland, PhD, Wolfgang E Berdel, MD, Bernhard J Woermann, MD, Wolfgang Hiddemann, MD, Thomas Buchner, MD, Carsten Müller-Tidow, MD

Blood (2009) 114 (22): 327.

https://doi.org/10.1182/blood.V114.22.327.327

Published: 2009

Journal Articles

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)

Blood (2009) 113 (21): 5250–5253.

https://doi.org/10.1182/blood-2008-09-172668

Published: 2009

Includes: Supplemental data

Journal Articles

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

Blood (2008) 112 (11): 2599.

https://doi.org/10.1182/blood.V112.11.2599.2599

Published: 2008

NARROW

D DX41 -Low Expression Mimics Germline DDX41 -Phenotype in Acute Myeloid Leukemia

Risk Stratification of Patients with RUNX1- mutated Acute Myeloid Leukemia

Genetic Characterization of Patients with Monoallelic and Biallelic CEBPA Mutations Using a Targeted Sequencing Approach Reveals Differences in the Spectrum of Cooperating Mutations

Up-Front Randomization 10 Years Later: The AML Cooperative Group Strategy

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Activating FLT3 Mutations Display a Wide Range Of Transforming Potential and a Characteristic Pathway Profile Associated With Prognosis In Acute Myeloid Leukemia

Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis

High Efficacy and Significantly Shortened Neutropenia Of Dose-Dense S-HAM As Compared To Standard Double Induction: First Results Of a Prospective Randomized Trial (AML-CG 2008)

Acute Myeloid Leukemia: The Outcome Is Determined By Age, Genetic Group, White Blood Cell Count, Lactate Dehydrogenase, Rather Than By Chemotherapy Intensity

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Allogeneic Stem Cell Transplantation Versus Conventional Postremission Therapy for Acute Myeloid Leukemia in First Complete Remission: A Matched Pairs Analysis

GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia

Front Line Treatment of Elderly Patients with Acute Promyelocytic Leukemia: Long-Term Results of the German AML Cooperative Group

Follow-up Analysis of a Randomized Comparison of Prolonged Myelosuppressive Maintenance Therapy Versus Intensive Consolidation Therapy as Postremission Therapy in AML.

Long-Term Results in Patients with Acute Myeloid Leukemia (AML): The Influence of High-Dose AraC, G-CSF Priming, Autologous Transplantation, Prolonged Maintenance, Age, History, Cytogenetics, and Mutation Status. Data of the AMLCG 1999 Trial.

A Novel Risk Score Predicts the Likelihood of a Complete Remission After Intensive Induction Therapy in Older AML Patients.

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)

Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only